Partial Agonist Morphinans for Analgesia with Reduced Addiction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current analgesics, particularly opioids, fail to effectively manage pain without causing significant side effects and addiction liability, necessitating the development of novel compounds that can provide potent analgesia with minimal side effects and no addiction risk.
Innovation Solution
Development of novel morphinan compounds with high binding affinities as partial agonists at mu, delta, and kappa opioid receptors, which are administered in pharmaceutical compositions to treat pain and opioid addiction, leveraging specific chemical structures and preparation methods to enhance efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional opioids are used for pain management, then analgesic efficacy is improved, but side effects and addiction liability increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of morphinan compounds through systematic variation of substituents at different positions (R1-R11 groups). This structural parameter optimization enables tuning of receptor binding affinity and agonist activity to achieve potent analgesia with reduced side effects and addiction liability compared to traditional opioids like morphine
Solution Approach 2:
The invention creates composite pharmacological effects by designing compounds that act as partial agonists at multiple opioid receptor types (mu, delta, and kappa receptors simultaneously). This multi-receptor composite action provides balanced analgesic efficacy while reducing the harmful effects associated with selective mu-agonism
2Reliability
If opioid dosage is increased to improve pain relief, then analgesic effect is enhanced, but side effects and respiratory depression worsen
Solution Approach 1:
The patent employs parameter changes by optimizing the chemical structure parameters of morphinan compounds to achieve high binding affinity and partial agonist activity at multiple receptor types. This structural optimization allows attainment of potent analgesic effects at lower doses, thereby avoiding the dose-dependent respiratory depression and side effects characteristic of traditional opioids
3Object-generated harmful factors
If morphinan structure is modified to reduce side effects, then safety is improved, but binding affinity and analgesic efficacy may decrease
Solution Approach 1:
The patent systematically applies parameter changes by varying substituent groups (R1-R11) at different positions of the morphinan core structure. This structured parameter optimization maintains high binding affinity to opioid receptors while modifying pharmacological properties to reduce side effects and addiction liability, achieving both safety and efficacy improvements
Solution Approach 2:
The invention achieves composite pharmacological profiles by designing compounds with balanced partial agonist activity at mu, delta, and kappa receptors. This multi-receptor composite action ensures maintained analgesic efficacy through combined receptor activation while reducing harmful effects associated with any single receptor type
Data Source
AI summary
Compounds of Formula (I) are disclosed.The variables R1-R11 are described herein. Certain compounds of Formula (I) are partial agonists of the mu, delta, and kappa opioid receptors, and are useful for treating pain and opioid addiction, with fewer side effects than conventional opioids. Methods for preparing the disclosed compounds, pharmaceutical compositions containing compounds of Formula (I), and methods of treating pain and opioid addiction in patients are also disclosed.